Freedom Capital Raises Target to $610; Barclays Lifts to $712 Citing da Vinci 5
Freedom Capital raised its price target for Intuitive Surgical from $560 to $610 and upgraded its rating to Buy, implying over 11% upside ahead of the da Vinci 5 rollout. Barclays analyst Matt Miksic lifted his target to $712 from $686 while keeping an Overweight stance after Intuitive’s Q4 report and matching 2026 forecasts.
1. Freedom Capital Upgrade
Freedom Capital increased its price target on Intuitive Surgical from $560 to $610 and upgraded its rating to Buy, attributing the change to elevated revenue forecasts over the next two years tied to new product introductions.
2. Barclays Price Target Revision
Barclays analyst Matt Miksic raised his price target on Intuitive Surgical to $712 from $686 and maintained an Overweight rating after the company’s fourth quarter results, noting that 2026 guidance aligns with prior estimates.
3. da Vinci 5 Launch Impact
The launch of the da Vinci 5 surgical system is expected to be a key driver of system sales and procedure volumes during 2026, underpinning the bullish outlook from both analysts.
4. Company Overview
Intuitive Surgical operates in the robotic-assisted surgery market, manufacturing flagship platforms including the da Vinci Surgical System and the Ion endoluminal system aimed at improving minimally invasive care.